GT Biopharma (GTBP)
NASDAQ:GTBP
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.39 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$12.90M
Enterprise Value-$2.47M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,553,892
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Platform (TriKE/TetraKE)GT Biopharma’s TriKE/TetraKE NK-cell engager platforms provide a proprietary, platform-style technology that can be applied across hematologic and solid tumors. Platform breadth supports multiple internal candidates, licensing or partnerships, creating durable pipeline optionality beyond one asset.
Low Leverage / Minimal DebtEssentially no debt reduces solvency and interest-rate risk for a clinical-stage biotech, preserving strategic flexibility. Low leverage lets management prioritize R&D, pursue collaborations, or tolerate longer development timelines without immediate debt-service constraints.
Improving Cash And Operating ProfileModest free cash flow improvement and reduced operating losses versus peak years indicate progress on cost discipline and program prioritization. If sustained, this trend extends runway, lowers near-term financing urgency and improves probability of hitting clinical milestones.
Bears Say
No Revenue; Large Recurring LossesThe company remains pre-revenue with substantial recurring losses, meaning fundamentals depend entirely on successful R&D outcomes or external deals. This prolongs the path to sustainable cash generation and increases reliance on financing or partnerships to continue operations.
Persistent Negative Operating Cash FlowConsistent negative operating cash flow erodes cash reserves and forces recurring capital raises that dilute shareholders and divert management attention to fundraising. Ongoing burn constrains ability to advance multiple programs concurrently and raises execution risk.
Eroding Shareholders' EquityDeclining and briefly negative equity reflects cumulative losses that weaken the capital base and reduce shock absorption. This condition can worsen fundraising terms, heighten counterparty concerns, and limit the firm’s ability to secure favorable partnerships or credit facilities.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.39 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $12.90M.
When is GT Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GT Biopharma’s earnings last quarter?
Currently, no data Available
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 31,553,892 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(310.96% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.71%
Insiders
0.08% Mutual Funds
0.70% Other Institutional Investors
96.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---